John E. Herrmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
John E. Herrmann has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Abraham L. Sonenshein
Department of Biomedical Sciences, Tufts University, Cummings School of Veterinary Medicine, North Grafton, Massachusetts 01536,1 Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts 02111,2 Department of Microbiology and Immunology, Tulane University Health Sciences Center, New Orleans, Louisiana 70112,3 Department of International Health, Boston University School of Public Health, Boston, Massachusetts 021184
1 shared publicationBoris R. Belitsky
Department of Biomedical Sciences, Tufts University, Cummings School of Veterinary Medicine, North Grafton, Massachusetts 01536,1 Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts 02111,2 Department of Microbiology and Immunology, Tulane University Health Sciences Center, New Orleans, Louisiana 70112,3 Department of International Health, Boston University School of Public Health, Boston, Massachusetts 021184
1 shared publicationDavid W. Brown
Department of Biomedical Sciences, Tufts University, Cummings School of Veterinary Medicine, North Grafton, Massachusetts 01536,1 Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts 02111,2 Department of Microbiology and Immunology, Tulane University Health Sciences Center, New Orleans, Louisiana 70112,3 Department of International Health, Boston University School of Public Health, Boston, Massachusetts 021184
1 shared publicationGerald T. Keusch
Department of Biomedical Sciences, Tufts University, Cummings School of Veterinary Medicine, North Grafton, Massachusetts 01536,1 Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts 02111,2 Department of Microbiology and Immunology, Tulane University Health Sciences Center, New Orleans, Louisiana 70112,3 Department of International Health, Boston University School of Public Health, Boston, Massachusetts 021184
1 shared publicationJames P. Brinker
Department of Biomedical Sciences, Tufts University, Cummings School of Veterinary Medicine, North Grafton, Massachusetts 01536,1 Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts 02111,2 Department of Microbiology and Immunology, Tulane University Health Sciences Center, New Orleans, Louisiana 70112,3 Department of International Health, Boston University School of Public Health, Boston, Massachusetts 021184
1 shared publicationJohn D. Clements
Department of Biomedical Sciences, Tufts University, Cummings School of Veterinary Medicine, North Grafton, Massachusetts 01536,1 Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts 02111,2 Department of Microbiology and Immunology, Tulane University Health Sciences Center, New Orleans, Louisiana 70112,3 Department of International Health, Boston University School of Public Health, Boston, Massachusetts 021184
1 shared publication
Latest Publications
- Open Access
- 1 November 2010
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 17 (11) , 1647-1655
Development of a Bacillus subtilis -Based Rotavirus Vaccine
Bacillus subtilis vaccine strains engineered to express either group A bovine or murine rotavirus VP6 were tested in adult mice for their ability to induce immune responses and provide protection against rotavirus challenge. Mice were inoculated intranasally with spores or vegetative cells of the recombinant strains of B. subtilis . To enhance mucosal immunity, whole cholera toxin (CT) or a mutant form (R192G) of Escherichia coli heat-labile toxin (mLT) were included as adjuvants. To evaluate vaccine efficacy, the immunized mice were challenged orally with EDIM EW murine rotavirus and monitored daily for 7 days for virus shedding in feces. Mice immunized with either VP6 spore or VP6 vegetative cell vaccines raised serum anti-VP6 IgG enzyme-linked immunosorbent assay (ELISA) titers, whereas only the VP6 spore vaccines generated fecal anti-VP6 IgA ELISA titers. Mice in groups that were immunized with VP6 spore vaccines plus CT or mLT showed significant reductions in virus shedding, whereas the groups of mice immunized with VP6 vegetative cell vaccines showed no difference in virus shedding compared with mice immunized with control spores or cells. These results demonstrate that intranasal inoculation with B. subtilis spore-based rotavirus vaccines is effective in generating protective immunity against rotavirus challenge in mice.
- 1 November 2010
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 17 (11) , 1647-1655
Open AccessDevelopment of a Bacillus subtilis -Based Rotavirus Vaccine
Bacillus subtilis vaccine strains engineered to express either group A bovine or murine rotavirus VP6 were tested in adult mice for their ability to induce immune responses and provide protection against rotavirus challenge. Mice were inoculated intranasally with spores or vegetative cells of the recombinant strains of B. subtilis . To enhance mucosal immunity, whole cholera toxin (CT) or a mutant form (R192G) of Escherichia coli heat-labile toxin (mLT) were included as adjuvants. To evaluate vaccine efficacy, the immunized mice were challenged orally with EDIM EW murine rotavirus and monitored daily for 7 days for virus shedding in feces. Mice immunized with either VP6 spore or VP6 vegetative cell vaccines raised serum anti-VP6 IgG enzyme-linked immunosorbent assay (ELISA) titers, whereas only the VP6 spore vaccines generated fecal anti-VP6 IgA ELISA titers. Mice in groups that were immunized with VP6 spore vaccines plus CT or mLT showed significant reductions in virus shedding, whereas the groups of mice immunized with VP6 vegetative cell vaccines showed no difference in virus shedding compared with mice immunized with control spores or cells. These results demonstrate that intranasal inoculation with B. subtilis spore-based rotavirus vaccines is effective in generating protective immunity against rotavirus challenge in mice.